Results of Eimskip's 2023 Annual General Meeting
Enclosed are the results of the Annual General Meeting of Eimskipafélag Íslands hf. held today, Thursday 9 March 2023, and updated Articles of Association of the Company.
Shareholders presenting 84.1% of the company's voting share participated in the meeting.
The Company will now request the Icelandic Register of Enterprises to grant the Company an exemption from the duty to issue a call to creditors, cf. Article 53.2 of the Act no. 2/1995 respecting Public Limited Companies.
Attachments
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
PRE ANNOUNCEMENT OF CERTIFICATE AUCTION TENDER8.5.2024 09:32:00 CEST | Press release
PRE ANNOUNCEMENT OF CERTIFICATE AUCTION TENDER MONETARY POLICY MEETING 2024-05-07 AUCTION PERIODS COMMENCING: 2024-05-15: FIXED RATE 3.75 % (VALID UNTIL NEXT MONETARY POLICY MEETING) DEPOSIT RATE 3.65 % LENDING RATE 3.85 %
Karolinska Developments portföljbolag Umecrine Cognition inleder andra delen av bolagets fas 1b/2-studie i PBC8.5.2024 09:30:46 CEST | Pressemelding
STOCKHOLM, SVERIGE 8 maj 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar att portföljbolaget Umecrine Cognition har randomiserat de första två patienterna till den andra delen av bolagets pågående kliniska fas 1a/2-studie med golexanolon i patienter med primär biliär kolangit, PBC. Top line-resultat beräknas presenteras under det första halvåret 2025. Umecrine Cognition utvecklar en helt ny typ av läkemedel för att lindra kognitiva symtom orsakade av leversjukdomar. Bolagets längst framskridna läkemedelskandidat golexanolon utvärderas för närvarande i en randomiserad, dubbelblind, placebokontrollerad klinisk fas 1b/2-studie i patienter med primär biliär kolangit, PBC, som upplever klinisk signifikant trötthet och kognitiva symtom. Efter klartecken från Umecrine Cognitions interna säkerhetsutvärderingskommitté, iSRC, att fortsätta till den andra delen av studien är målet nu att utvärdera den preliminära effekten av golexanolon samt att fortsätta dokumentera läkemedelsk
Karolinska Development’s portfolio company Umecrine Cognition initiates second part of clinical phase 1a/2 study in PBC8.5.2024 09:30:46 CEST | Press release
STOCKHOLM, SWEDEN – May 8, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition has randomized its first two patients to the second part of the ongoing clinical phase 1b/2 study of golexanolone in patients with Primary Biliary Cholangitis, PBC. Top-line results are expected in first half of 2025. Umecrine Cognition is developing a new class of drugs to alleviate cognitive symptoms caused by liver disease. The company's most advanced drug candidate, golexanolone, is currently being evaluated in a randomized, double-blind, placebo-controlled, clinical phase 1b/2 study in patients with primary biliary cholangitis (PBC) who experience clinically significant fatigue and cognitive symptoms. Following recent authorization from Umecrine Cognitions internal safety review committee (iSRC), to proceed to the second part of the study, the aim is now to evaluate the preliminary efficacy of golexanolone, as well as continue the docume
IDEX Biometrics is bringing biometric cards to market with large smart card manufacturer in South Asia8.5.2024 09:30:00 CEST | Press release
Oslo, Norway, 8 May 2024 – IDEX Biometrics and one of the largest smart card manufacturers in South Asia are deploying smart cards across Asia and globally. With over 3 billion cards manufactured to date and a production capacity of 25 million cards monthly, this partner will support IDEX Biometrics continued expansion and growth across Asia Pacific, Middle East, Africa, and the USA. Accredited by Visa, Mastercard and RuPay and with a growing client portfolio of banks, government agencies, telecom companies, transportation authorities, and corporate enterprises, the partner’s strong market position will accelerate go-to-market of biometric payment and access cards. These biometric smart cards, based on IDEX Pay and IDEX Access, are expected to reach the market by the end of 2024. "This is another testament to IDEX Biometrics strategic focus and expansion in Asia," commented Catharina Eklof, Chief Commercial Officer of IDEX Biometrics. "The recognized technology expertise in smart card
Interim Report Q1 20248.5.2024 09:12:21 CEST | Press release
2024 off to a good start with continued revenue growth Revenue growth of 14% in Q1 2024, primarily arising from our key Cloud ERP Business Lines, Dynamics and M3. EBITDA amounted to DKK 55m, corresponding to an EBITDA margin of 12.4%. Excluding a net gain of DKK 20m from settlement of M3CS legal case, the EBITDA margin was 7.9%. Overall, a satisfactory start to the year. “We came off to a good start of the year driven by strong performance in our Cloud ERP business. Our customers’ focus on safeguarding critical business systems is currently reshaping demand, thus underlining the strength of our end-to-end portfolio of services in a wide range of markets,” says CEO & President, Søren Krogh Knudsen Q1 2024 highlights Revenue growth of 14% amounting to DKK 444m. 11% growth adjusted for acquisitions and currency.EBITDA amounted to DKK 55m. DKK 35m adjusted for the M3CS legal case.EBITDA margin was 12.4% compared to 10.0% in Q1 2023. Adjusted for the M3CS legal case, EBITDA margin was 7.9%.